2017
DOI: 10.1038/sdata.2017.90
|View full text |Cite
|
Sign up to set email alerts
|

A multi-protease, multi-dissociation, bottom-up-to-top-down proteomic view of the Loxosceles intermedia venom

Abstract: Venoms are a rich source for the discovery of molecules with biotechnological applications, but their analysis is challenging even for state-of-the-art proteomics. Here we report on a large-scale proteomic assessment of the venom of Loxosceles intermedia, the so-called brown spider. Venom was extracted from 200 spiders and fractioned into two aliquots relative to a 10 kDa cutoff mass. Each of these was further fractioned and digested with trypsin (4 h), trypsin (18 h), pepsin (18 h), and chymotrypsin (18 h), t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
27
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 23 publications
(30 citation statements)
references
References 56 publications
1
27
0
Order By: Relevance
“…In addition, a comprehensive profile of Loxosceles intermedia crude venom toxins was obtained by the digestion of the venom followed by the separation of fragments using UHPLC liquid chromatography and analysis by mass spectrometry (ORBITRAP). The final data showed the presence of peptides compatible with different members of the PLD family in the venom, confirming the existence of a large intra-species family of these molecules [77].…”
Section: Proteomic Analysis In the Learning About Brown Spider Venom supporting
confidence: 55%
“…In addition, a comprehensive profile of Loxosceles intermedia crude venom toxins was obtained by the digestion of the venom followed by the separation of fragments using UHPLC liquid chromatography and analysis by mass spectrometry (ORBITRAP). The final data showed the presence of peptides compatible with different members of the PLD family in the venom, confirming the existence of a large intra-species family of these molecules [77].…”
Section: Proteomic Analysis In the Learning About Brown Spider Venom supporting
confidence: 55%
“…The effects of L. intermedia crude venom on RBL-2H3 degranulation ( Figure 2C) are related to the histaminergic effects of Loxoscelism. The report of TCTP-related toxins in the Loxosceles venoms were previously done by transcriptomic studies using venom gland transcripts [1], by cloning and recombinant expression of LiRecTCTP [2], and recently, TCTP was identified in the proteomic study of the L. intermedia venom [32]. Additionally, TCTP was immunodetected in the whole venom of Loxosceles species (L. intermedia, L. gaucho, and L. laeta) [3], pointing to conservation and biological relevance.…”
Section: Discussionmentioning
confidence: 99%
“…LC-MS/MS can be conducted with a variety of analyzers including the lower-massresolving ion trap and triple quadrupole instruments, intermediate resolving power quadrupole-quadrupole-TOF (QqTOF) instruments, and higher-resolving-power triple-quadropole-TOF (QqQ-TOF), Orbitrap or FT-ICR instruments. LC-MS/MS using DDA is the most common method for obtaining venom peptide fragmentation data in many laboratories, [22,25,[48][49][50][51][52]57,[65][66][67][68][69][70][71][72][73][74][75][76][77][78][79] including ours. [29,42,43,53,61,[80][81][82][83] These data are typically searched using an automated algorithm against a database of protein sequences to identify peptide primary structures.…”
Section: De Novo Peptide Sequencingmentioning
confidence: 99%
“…Taken together, CID, ETD, and ECD provide complementary fragmentation data that can be valuable for de novo sequencing, [67][68][69][70] particularly in hybrid mass spectrometers, such as the LTQ-Orbitrap family, that have parallel scanning capability allowing simultaneous collection of high-resolution MS data and lower resolution ion trap MS/MS data. For example, Ueberheide et al [84] developed an ETD-based de novo sequencing method specifically tailored to disulfide-rich venom peptides.…”
Section: De Novo Peptide Sequencingmentioning
confidence: 99%
See 1 more Smart Citation